Irinotecan (Campto®) in the treatment of pancreatic cancer Journal Article
| Authors: | Pizzolato, J.; Saltz, L. B. |
| Article Title: | Irinotecan (Campto®) in the treatment of pancreatic cancer |
| Abstract: | Irinotecan (Campto®) is a topoisomerase I inhibitor currently approved for the treatment of metastatic colon cancer. Single-agent irinotecan has also demonstrated modest activity in a number of other advanced solid tumors, including lung, gastric and pancreatic cancer. Preclinical data suggest a potentially additive and/or synergistic interaction between irinotecan and gemcitabine (Gemzar®). This combination has demonstrated improved response rates in patients with pancreatic cancer. Unfortunately, a recently reported Phase III trial of gemcitabine with or without irinotecan revealed no survival benefit for the combination. Future combinations of irinotecan continue to be explored in an effort to further improve the treatment of this relatively chemorefractory disease. Thus far, no single agent or combination has been shown to be superior to gemcitabine alone as palliative therapy for advanced/metastatic pancreatic cancer. A promising combination of irinotecan with oxaliplatin (Eloxatin®) and fluorouracil will be assessed in a Phase III study. |
| Keywords: | survival; cancer survival; drug activity; neutropenia; review; bevacizumab; cisplatin; fluorouracil; diarrhea; drug potentiation; solid tumor; drug approval; gemcitabine; cancer patient; pancreas cancer; pancreatic neoplasms; antineoplastic agent; cancer palliative therapy; animal; animals; metastasis; phase 2 clinical trial; anemia; thrombocytopenia; peripheral neuropathy; 7 ethyl 10 hydroxycamptothecin; antineoplastic agents, phytogenic; camptothecin; lung cancer; drug structure; docetaxel; irinotecan; drug mechanism; drug combination; folinic acid; colon cancer; pancreas tumor; drug response; drug derivative; drug clearance; stomach cancer; mitomycin c; phase 3 clinical trial; pancreatic cancer; drug blood level; phase 1 clinical trial; drug half life; drug combinations; dna topoisomerase inhibitor; combination therapy; oxaliplatin; granulocyte colony stimulating factor; atropine; drug indication; raltitrexed; response rate; clinical trials, phase ii; clinical trials, phase iii; clinical trials, phase i; humans; human; article |
| Journal Title: | Expert Review of Anticancer Therapy |
| Volume: | 3 |
| Issue: | 5 |
| ISSN: | 1473-7140 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2003-10-01 |
| Start Page: | 587 |
| End Page: | 593 |
| Language: | English |
| PUBMED: | 14599083 |
| PROVIDER: | scopus |
| DOI: | 10.1586/14737140.3.5.587 |
| DOI/URL: | |
| Notes: | Export Date: 12 September 2014 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work